Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

Shots:Garret spoke about the approval of the first NGS-based companion diagnostic to aid in selecting NSCLC patients with HER2 activating mutations for treatment with ENHERTUGarret also talked about the Oncomine Dx Target Test and its availability for different targeted therapies in multiple geographiesThe interview highlights how Thermo Fisher is working to develop accessible CDx solutions…

BySenior EditorOctober 25, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industryThe Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021Additionally, last year in 2020, the US FDA…

BySenior EditorJuly 7, 2021

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

PharmaShots’ Key Highlights of Second Quarter 2021

Contact US

OUR INFORMATION

FOLLW US

Garret Hampton, President, Clinical Sequencing & Oncology at Thermo Fisher Scientific Shares Insights from the Approval of the First NGS-Based Companion Diagnostic for HER2-Mutant NSCLC

PharmaShots’ Key Highlights of Second Quarter 2021

FOLLW US

Sign Up to Our Newsletter